Ophthalmology Management - January 2023
Topline results from DERBY, OAKS may pave way to first treatment for geographic atrophy
Apellis Announces 18-Month Data from Phase 1b Study of Pegcetacoplan in Patients with Geographic Atrophy (GA) | BioSpace
Apellis finds that one of its twins is evil | Evaluate
A New Era in Dry AMD Treatment | Duke Department Of Ophthalmology
SYFOVRE™ (pegcetacoplan injection) OAKS and DERBY efficacy
Association of complement C3 inhibitor pegcetacoplan with reduced photoreceptor degeneration beyond areas of geographic atrophy | Scientific Reports
%20copy_1661347616.jpg "Apellis Announces 24-Month Results in Phase 3 Studies Examining Pegcetacoplan in Geographic Atrophy (GA)")
Apellis Announces 24-Month Results in Phase 3 Studies Examining Pegcetacoplan in Geographic Atrophy (GA)
The potential impact of pegcetacoplan
%20copy_1651527917.jpg "Apellis Announces Detailed 18-Month Results from Phase 3 DERBY and OAKS Studies of Pegcetacoplan for Geographic Atrophy (GA)")
Apellis Announces Detailed 18-Month Results from Phase 3 DERBY and OAKS Studies of Pegcetacoplan for Geographic Atrophy (GA)
First Geographic Atrophy Drug Approved
Clinical trial OAKS-DERBY: efficacy and safety of pegcetacoplan in the treatment of geographic atrophy secondary to AMD | Institut de la Màcula
Angiogenesis 2023: DERBY, OAKS clinical trials for geographic atrophy demonstrate safety, efficacy
Apellis Announces Detailed 18-Month Results from Phase 3 DERBY and OAKS Studies of Pegcetacoplan for Geographic Atrophy (GA) at ARVO Annual Meeting
Syfovre (pegcetacoplan) to Treat Geographic Atrophy, USA
Apellis Pushing Forward in Macular Degeneration Despite Mixed Results | BioSpace
Duke Researchers and Leaders in Two Clinical Trials Aim to Find Treatment for Geographic Atrophy | Duke Department Of Ophthalmology
Recruiting patients with geographic atrophy secondary to AMD for phase 3 trials | Apellis APL-2 Opthalmic Trial
Apellis Pharmaceuticals provides update on its Phase 3 program
Overview of DERBY and OAKS Studies
Recruiting patients with geographic atrophy secondary to AMD for phase 3 trials | Apellis APL-2 Opthalmic Trial
SYFOVRE™ (pegcetacoplan injection) OAKS and DERBY efficacy
FDA Approves Apellis' Syfovre (Pegcetacoplan), First and Only Treatment for Geographic Atrophy
SYFOVRE™ (pegcetacoplan injection) OAKS and DERBY efficacy
Gaining Ground on Geographic Atrophy
